Signal‐transducing innate receptors in tumor immunity
Open Access
- 11 February 2021
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 112 (7), 2578-2591
- https://doi.org/10.1111/cas.14848
Abstract
The signal transducing innate receptors represent classes of pattern recognition receptors (PRRs) that play crucial roles in the first line of host defense against infections by the recognition of pathogen‐derived molecules. Because of their poorly discriminative nature compared to the antigen receptors of the adaptive immune system, they also recognize endogenous molecules and evoke immune responses without infection, resulting in the regulation of tumor immunity. Hence, PRRs may be the promising targets for effective cancer immunotherapy either by activating or inhibiting them. Here, we summarize our current knowledge of signal‐transducing PRRs in the regulation of tumor immunity.Keywords
This publication has 119 references indexed in Scilit:
- Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cellsCell Death & Disease, 2013
- Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4Cancer Cell, 2012
- Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesisInflammatory Bowel Diseases, 2011
- TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cellsThe EMBO Journal, 2010
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- C-type lectins and phagocytosisImmunobiology, 2009
- Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumorsInflammatory Bowel Diseases, 2009
- Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasisNature, 2009
- Pathogen Recognition and Innate ImmunityCell, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002